Enwei Pharmaceuticals: Independent Directors’ 2025 Annual Work Report (Li Chun)

2025 Annual Work Report of Enwei Pharmaceutical Independent Director Li Chun

Enwei Pharmaceutical Co., Ltd.

Independent Directors’ 2025 Annual Work Report

Dear shareholders and shareholder representatives:

I, Li Chun, serve as an independent director of the third board of directors of Enwei Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") in 2025 During the year, I acted in accordance with laws and regulations such as the Company Law of the People's Republic of China, the Securities Law of the People's Republic of China, the GEM Stock Listing Rules of the Shenzhen Stock Exchange, the Management Measures for Independent Directors of Listed Companies, as well as the Articles of Association of Enwei Pharmaceutical Co., Ltd. and the Company's Independent Director Work System. " and other regulations, faithfully and diligently performed their duties, exercised their powers independently and prudently, actively and proactively understood the company's operating conditions, made full use of professional knowledge to express objective and impartial independent opinions on major company matters, and effectively safeguarded the legitimate rights and interests of the company and all shareholders, especially small and medium-sized shareholders. The performance report for 2025 is now as follows:

1. My basic situation

Li Chun, female, Chinese nationality, born in February 1978, has no permanent residence abroad. Doctoral degree, graduated from Southwestern University of Finance and Economics majoring in financial management. From July 2003 to present, he works at Southwestern University of Finance and Economics as a professor and doctoral supervisor. From January 2024 to present, he concurrently serves as an independent director of the company.

I do not hold any other position in the company except as an independent director, nor do I hold any position among the major shareholders of the company. I have no trading relationship or family relationship with the company. I regularly participate in professional training organized by the Shenzhen Stock Exchange, which complies with the independence requirements of the China Securities Regulatory Commission's "Administrative Measures for Independent Directors of Listed Companies" and there are no circumstances that affect my independence.

2. Annual performance of independent directors’ duties

1. Attendance at this year’s board of directors and shareholders’ meetings

In 2025, the company held a total of 4 board meetings and 1 shareholders' meeting. As an independent director, I attended the meetings and participated in the board voting. In order to fully perform my duties as an independent director, I carefully reviewed relevant proposals, took the initiative to understand the relevant situations, used my professional knowledge and abilities to make independent judgments, and put forward reasonable opinions and suggestions on relevant major matters rigorously, objectively and impartially. I gave full play to the role of an independent director and safeguarded the overall interests of the company and the interests of small and medium-sized shareholders.

2025 Annual Work Report of Enwei Pharmaceutical Independent Director Li Chun

I believe that: the company's board of directors meetings and shareholders' meetings are convened in compliance with legal procedures, and relevant approval procedures have been fulfilled for major business decision-making matters and other major matters. During the reporting period, the independent directors did not raise objections to various proposals of the board of directors and other matters of the company.

Details of attendance at the 2025 Board of Directors:

Independent directors should attend. Attend on-site. Participate by communication. Attend by proxy. Absent name. Number of times. Number of times. Number of meetings. Number of times. Li Chun 4 2 2 0 0 Attendance at the 2025 shareholders' meeting:

Name of independent director Number of meetings attended

Li Chun 1

2. Attendance at special meetings of independent directors

In 2025, I strictly abide by the "Shenzhen Stock Exchange GEM Stock Listing Rules", "Shenzhen Stock Exchange Self-Regulatory Supervision Guidelines for Listed Companies No. 2 - Standardized Operation of GEM Listed Companies", "Measures for the Management of Independent Directors of Listed Companies" and other relevant laws and regulations, as well as the provisions of the "Articles of Association" and "Independent Director Work System", and participated in a total of 1 special meeting of independent directors throughout the year. The details are as follows:

Session of the meeting Date of the meeting Issue of independent opinions

The third session of the Board of Directors specifically reviewed and approved the following proposals:

April 18, 2025

The second meeting of the meeting: Proposal on the expected daily related transactions of the company in 2025

3. Performance of duties by special committees of the board of directors

The company's third board of directors has established three special committees, namely the Strategy and Development Committee, the Audit Committee, and the Nomination and Remuneration Committee. The company has formulated corresponding systems to regulate the operation of each special committee.

During the reporting period, I served as a member of the Nomination and Remuneration Committee of the third session of the Board of Directors and a member of the Strategy and Development Committee of the third session of the Board of Directors. The company performs its duties in accordance with the work system of the company's special committees, and plays the role of each special committee in supporting and supervising the board of directors' decision-making.

(1) Remuneration and Appraisal Committee

2025 Annual Work Report of Enwei Pharmaceutical Independent Director Li Chun

During the reporting period, as a member of the Nomination and Remuneration Committee of the third session of the Board of Directors of the Company, I participated in the daily work of the Nomination and Remuneration Committee of the Board of Directors in strict accordance with the "Working System of the Nomination and Remuneration Committee of the Board of Directors" and other relevant regulations. In 2025, the Nomination and Remuneration Committee of the third board of directors held a total of 2 meetings. I was supposed to attend 2 meetings and actually attended 2 meetings to review the company's equity incentive plan, the remuneration and plan-related matters of the company's directors and senior managers, and effectively perform the duties of a member of the Nomination and Remuneration Committee.

(2) Strategy and Development Committee

During the reporting period, as a member of the Strategy and Development Committee of the third session of the Board of Directors, I exercised my powers in strict accordance with the "Working System of the Strategy and Development Committee of the Board of Directors". As a member of the Strategy and Development Committee of the Board of Directors, I have always paid attention to the development status of the company's industry and changes in industry policies, as well as the company's strategic layout in the industry, products, marketing, brand, etc., and maintained information communication with the company's management and key personnel through multiple channels, and kept abreast of the company's latest operations. During the reporting period, after the company successfully acquired Henan Xinxin Pharmaceutical the year before last, it quickly promoted the resumption of production and sales of Xinxin Pharmaceutical's key products, and some of them had achieved mass production and market sales by the end of 2025. With the batch sales of Henan Confidence products, the company's operating indicators will be greatly optimized, and the company's product competitiveness and market voice will be greatly enhanced, laying a solid foundation for future development.

4. Circumstances in which special powers are exercised

In 2025, I did not exercise the special powers of an independent director.

5. Communication with internal audit institutions and accounting firms

During the reporting period, I actively communicated with the company's financial director, internal audit department and accounting firm, and carefully reviewed the company's financial system, financial management, and operating results during the reporting period. I believe that: the company's financial system is sound, financial management is standardized, financial status is good, and there are no violations of relevant laws and regulations; the 2025 annual financial report truly and objectively reflects the company's financial status, operating results, and cash flow. The standard unqualified audit report issued by the company's 2025 auditor ShineWing Certified Public Accountants (Special General Partnership) for the company is objective, fair, true and credible.

6. Communication with small and medium-sized shareholders

In 2025, I will use various channels to understand the related transactions, external investments, appointment of senior managers, equity incentives and other matters that are of concern to small and medium-sized shareholders, and provide timely feedback to the company's management. In the decision-making process, I will also focus on safeguarding the interests of the company and all shareholders, paying special attention to the legitimate rights and interests of small and medium-sized shareholders.

3. On-site investigation of the company

2025 Annual Work Report of Enwei Pharmaceutical Independent Director Li Chun

During my tenure in 2025, I will pay close attention to the company's operating activities. In addition to taking the opportunity to attend the company's shareholders' meeting, special independent director meetings, board of directors, and special committee meetings to conduct on-site investigations at the company, I will also maintain long-term communication with the company's directors, senior executives and related personnel through on-site work, phone calls, emails and other methods. I will carefully understand the company's daily operations, financial status, internal control operations and implementation progress, and put forward professional suggestions and ideas on the company's relevant work ideas and plans, and actively play the role of independent directors. During the reporting period, I worked on-site for 15 days.

4. Matters of focus in annual performance of duties by independent directors

1. Related transactions that should be disclosed

The related-party transactions that should be disclosed during the reporting period have been determined fairly, fairly and impartially in accordance with the provisions of the current laws and regulations and the Articles of Association and in accordance with market-oriented principles, and the necessary review and disclosure procedures have been performed. There has been no harm to the interests of the company and all shareholders, especially small and medium-sized shareholders.

2. Regular reporting of relevant matters

During the reporting period, the company prepared, reviewed and disclosed periodic reports on time in strict accordance with relevant regulations, and presented the company's operating conditions and financial status to investors in a true, accurate, complete, timely and fair manner. All directors and senior managers of the company have signed written confirmation opinions on the company's regular reports.

3. External guarantees and capital occupation

During the reporting period, the company did not provide guarantees for the controlling shareholders, actual controllers and their related parties, or any legal entities or individuals, nor did the controlling shareholders, actual controllers and their related parties occupy the company's funds for non-operational purposes.

4. Remuneration of directors and senior management personnel

During the reporting period, I reviewed the remuneration situation of the company's senior managers. After verification, I believe that: the remuneration plan complies with relevant national policies and the provisions of the "Articles of Association", the remuneration standards are reasonable, and can reflect the incentive and restraint mechanism that links the company's business objectives and performance with the income of the company's senior managers; the company's remuneration to directors and senior managers is in line with the company's remuneration policy and performance appraisal standards, and is paid in strict accordance with the assessment results. There are no violations of the company's remuneration management system.

5. Use of raised funds

According to the "Regulatory Guidelines for Listed Companies No. 2 - Supervisory Requirements for the Management and Use of Funds Raised by Listed Companies" and "Shenzhen Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 2 - Standards for GEM Listed Companies 2025 Annual Work Report of Independent Directors of Yun Enwei Pharmaceuticals Li Chun

"Operations" and other laws and regulations, normative documents, and relevant company regulations. I focused on supervising and reviewing the use of the company's raised funds. I believe that the storage and use of the company's raised funds fully complies with the requirements of relevant laws and regulations, and there are no violations.

6. Matters related to equity incentives

During the reporting period, the company promoted the implementation of the restricted stock incentive plan in an orderly manner in accordance with relevant laws and regulations such as the Company Law, the Securities Law, the Measures for the Administration of Equity Incentives for Listed Companies, and the company's relevant draft incentive plans, including the assessment of the vesting conditions for the second phase of the second phase of the 2023 restricted stock incentive plan, the adjustment of the grant price of the second type of restricted stock, the invalidation of the second type of restricted stock that has been granted but has not yet vested, etc. After verification, the company's equity incentive-related matters have completed the necessary review procedures. The procedures are legal and effective, and there is no harm to the interests of the company and all shareholders, especially small and medium-sized shareholders.

7. Cash dividends and other investor returns

During the reporting period, the company's 2024 annual shareholders' meeting reviewed and approved the "Proposal on the Company's 2024 Profit Distribution Plan". The company will use the total share capital on the equity registration date when implementing the profit distribution plan minus the number of shares in the company's repurchase of treasury shares in the special securities account as the base number to distribute a cash dividend of 1.80 yuan (tax included) to all shareholders for every 10 shares. At the same time, the company's shareholders meeting authorized the board of directors to formulate and implement the 2025 mid-term (including semi-annual report, third quarterly report, etc.) dividend plan within the scope of authorization.

On December 26, 2025, the ninth meeting of the company's third board of directors reviewed and approved the "Proposal on the Company's 2025 Interim Dividend Plan" and decided to use the total share capital on the equity registration date of the profit distribution plan minus the company's repurchase of shares in the special account as the distribution base, and distribute a cash dividend of RMB 3.50 (tax included) to all shareholders for every 10 shares.

I believe that the company's profit distribution plan is formulated based on the company's actual operating conditions and current financial status, taking into account the company's long-term development and the current interests of shareholders, and is in line with the relevant provisions of the "Company Law" and "Articles of Association", as well as the China Securities Regulatory Commission's guidance on encouraging listed companies to distribute cash dividends and provide investors with stable and reasonable returns.

8. Implementation of internal control

During the reporting period, I verified the company’s internal control system and operation, and reviewed the Board of Directors’ 2024 Internal Control Self-Evaluation Report. I believe that the company's internal control mechanism is operating well in 2024. The relevant rules, regulations and business operating procedures are in compliance with the requirements of relevant laws and regulations such as the "Accounting Law of the People's Republic of China", "Enterprise Accounting Standards" and "Basic Standards for Enterprise Internal Control", and can be effectively implemented. Li Chun, Independent Director of Enwei Pharmaceuticals 2025 Annual Work Report

The company's internal control objectives are achieved, and there are no major flaws in the design or execution of internal controls. The company's internal control evaluation report truly and objectively reflects the construction and operation of the company's internal control system.

5. Overall evaluation and suggestions

In 2025, as an independent director of the company, I maintained good communication with the management, performed my duties stipulated in laws, regulations, normative documents and the company's internal system, performed my duties diligently and diligently, actively participated in the company's special meetings of independent directors, board of directors and special committee meetings, carefully reviewed relevant proposals or made suggestions, which provided substantial help for the company's sustained and steady development, and effectively safeguarded the interests of the company and shareholders.

In 2026, I will continue to uphold the spirit of integrity, prudence and diligence, actively perform the duties of an independent director, actively pay attention to the development direction of the pharmaceutical industry, especially the traditional Chinese medicine industry, and the company's operating dynamics, and make full use of my professional knowledge and experience to provide suggestions for the company's development. At the same time, I will continue to strengthen communication and collaboration with the company, promote the further improvement of the company's governance structure, promote the company's higher-quality development, and effectively safeguard the overall interests of the company and the interests of small and medium-sized shareholders.

2025 Annual Work Report of the Independent Directors of Enwei Pharmaceuticals Li Chun (This page has no text, it is the signature page of the "2025 Annual Work Report of the Independent Directors of Enwei Pharmaceuticals Co., Ltd.")

Independent Director:

---

Li Chun

Date: April 24, 2026